Share Price, Q3 Earnings Live Updates: Focus on Jio IPO buzz, O2C growth, and reduced Russian oil imports. Get the latest ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
GSK touted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback